




PHARMACEUTICAL 2018

AXIM BIOTECHNOLOGIES INC.
Rank 316 of 342





PHARMACEUTICAL 2018

AXIM BIOTECHNOLOGIES INC. Rank 316 of 342

The relative strengths and weaknesses of AXIM BIOTECHNOLOGIES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AXIM BIOTECHNOLOGIES INC. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 23% points. The greatest weakness of AXIM BIOTECHNOLOGIES INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 120% points.

The company's Economic Capital Ratio, given in the ranking table, is -281%, being 326% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	2,113
Cost of Goods Sold	43
Intangible Assets	63
Liabilities, Current	7,705
Liabilities, Non-Current	772
Other Assets	7.4
Other Compr. Net Income	0
Other Expenses	3.4
Other Liabilities	0
Other Net Income	-1,019
Other Revenues	48
Property and Equipment	8.9
Research and Development	1,353
Selling, General and Administrative Expense	1,797

Output Variable	Value in 1000 USD
Assets	2,192
Liabilities	8,477
Expenses	3,197
Revenues	48
Stockholders Equity	-6,284
Net Income	-4,168
Comprehensive Net Income	-4,168
Economic Capital Ratio	-281%